Cellular Biomedicine Group is a biopharmaceutical company that develops treatments for cancerous and degenerative diseases. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The Company develops treatments utilizing proprietary cell-based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell-specific dendritic cell therapy.
Type
Public
HQ
Cupertino, US
Founded
2009
Size (employees)
109 (est)
Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, US
Report incorrect company information

Cellular Biomedicine Group Office Locations

Cellular Biomedicine Group has offices in Shanghai, Beijing, Hong Kong and Cupertino
Cupertino, US (HQ)
100 19925 Stevens Creek Blvd
Beijing, CN
Nongda South Road
Shanghai, CN
333 Guiping Road
Hong Kong , HK
No. 8 Cotton Tree Drive
Show all (4)
Report incorrect company information

Cellular Biomedicine Group Financials and Metrics

Cellular Biomedicine Group Financials

Cellular Biomedicine Group's revenue was reported to be $336.82 k in FY, 2017
USD

Revenue (Q1, 2018)

51 k

Gross profit (Q1, 2018)

28.7 k

Gross profit margin (Q1, 2018), %

56.2%

Net income (Q1, 2018)

(8.5 m)

EBIT (Q1, 2018)

(8.5 m)

Market capitalization (22-Jun-2018)

345.2 m

Closing share price (22-Jun-2018)

20.3

Cash (31-Mar-2018)

45.6 m
Cellular Biomedicine Group's current market capitalization is $345.2 m.
Annual
USDFY, 2016FY, 2017

Revenue

627.9 k336.8 k

Cost of goods sold

860.4 k162.2 k

Gross profit

(232.5 k)174.6 k

Gross profit Margin, %

(37%)52%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

603.4 k657 k624.9 k488.5 k71.6 k10 k98.4 k51 k

Cost of goods sold

52 k459 k398.2 k443.4 k503.2 k323.6 k9.1 k37.4 k22.3 k

Gross profit

144.4 k258.7 k181.5 k(14.7 k)(252 k)884 61 k28.7 k

Gross profit Margin, %

24%39%29%(3%)(352%)9%62%56%
Annual
USDFY, 2016FY, 2017

Cash

39.3 m21.6 m

Accounts Receivable

412.7 k

Inventories

Current Assets

40.7 m24.5 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

13.6 m9.8 m31.1 m23.7 m20.1 m15.7 m47.5 m44.1 m33.4 m45.6 m

Accounts Receivable

24 k175.1 k340 k445.2 k410.8 k582.7 k245.1 k264.8 k813.1 k

Inventories

156.5 k347.8 k277.9 k400.1 k422.1 k486.3 k313.8 k253.2 k

Current Assets

14.2 m11.1 m32.6 m25.5 m21.7 m17.7 m49.2 m45.3 m35.3 m48.7 m
Annual
USDFY, 2016FY, 2017

Net Income

(28.2 m)(25.5 m)

Depreciation and Amortization

2.6 m3 m

Inventories

514.7 k

Accounts Payable

(28.2 k)(814 )
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.7 m)(2.8 m)(4.3 m)(5 m)(5.1 m)(4.2 m)(7.2 m)(10.7 m)(6.2 m)(8.5 m)

Depreciation and Amortization

1.2 m

Inventories

156.5 k347.8 k277.9 k400.1 k422.1 k486.3 k313.8 k253.2 k

Accounts Payable

109.1 k224.4 k160.2 k106.6 k146.4 k208.9 k136.4 k220.2 k782.5 k26.6 k
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Cellular Biomedicine Group Online and Social Media Presence

Embed Graph
Report incorrect company information